机译:International Bladder Cancer Group Consensus Statement on Clinical Trial Design for Patients with Bacillus Calmette-Guérin–exposed High-risk Non–muscle-invasive Bladder Cancer
Vancouver Prostate Centre Department of Urologic Sciences University of British Columbia;
Department of Urology MD Anderson Cancer Center;
Perelman Center for Advanced Medicine University of Pennsylvania Division of Urology Department ofScott Department of Urology Dan L. Duncan Cancer Center Baylor College of MedicineDepartment of Surgery (Urology) Faculty of Medicine McGill UniversityDepartments of Urology University of LübeckDepartment of Urology Hesperia HospitalNorth York General HospitalDepartment of Urology Southmead Hospital North Bristol Hospitals TrustClaude Bernard University H?pital Edouard HerriotUniversity of Arizona and BCG OncologyDepartment of Urology Fundació Puigvert Universidad Autónoma de BarcelonaDivision of Urology Memorial Cancer Institute Memorial HospitalPatient Advocate National Cancer Institute Bladder Cancer Task ForceDepartment of Urology NYU Langone HealthDepartment of Urology UT Southwestern Medical Center at DallasEuropean Association of Urology Guidelines OfficeDepartment of Urology Radboud University Medical Center;
Bacillus Calmette-Guérin; Clinical trials; Intravesical therapy; Non–muscle-invasive bladder cancer; Risk stratification;